|
1
|
Carhill AA, Litofsky DR, Ross DS, Jonklaas
J, Cooper DS, Brierley JD, Ladenson PW, Ain KB, Fein HG, Haugen BR,
et al: Long-term outcomes following therapy in differentiated
thyroid carcinoma: NTCTCS registry analysis 1987–2012. J Clin
Endocrinol Metab. 100:3270–3279. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Scheffel RS, Zanella AB, Dora JM and Maia
AL: Timing of radioactive iodine administration does not influence
outcomes in patients with differentiated thyroid carcinoma.
Thyroid. 26:1623–1629. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kwong N, Marqusee E, Gordon MS, Larsen PR,
Garber JR, Kim MI and Alexander EK: Long-term, treatment-free
survival in select patients with distant metastatic papillary
thyroid cancer. Endocr Connect. 3:207–214. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Brink JS, van Heerden JA, McIver B,
Salomao DR, Farley DR, Grant CS, Thompson GB, Zimmerman D and Hay
ID: Papillary thyroid cancer with pulmonary metastases in children:
Long-term prognosis. Surgery. 128:881–887. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Goffredo P, Sosa JA and Roman SA:
Differentiated thyroid cancer presenting with distant metastases: A
population analysis over two decades. World J Surg. 37:1599–1605.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Haugen BR: 2015 American thyroid
association management guidelines for adult patients with thyroid
nodules and differentiated thyroid cancer: What is new and what has
changed? Cancer. 123:372–381. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nixon IJ, Wang LY, Migliacci JC, Eskander
A, Campbell MJ, Aniss A, Morris L, Vaisman F, Corbo R, Momesso D,
et al: An international multi-institutional validation of age 55
years as a cutoff for risk stratification in the AJCC/UICC staging
system for well-differentiated thyroid cancer. Thyroid. 26:373–380.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Machiels JP, Henry S, Zanetta S, Kaminsky
MC, Michoux N, Rommel D, Schmitz S, Bompas E, Dillies AF, Faivre S,
et al: Phase II study of sunitinib in recurrent or metastatic
squamous cell carcinoma of the head and neck: GORTEC 2006-01. J
Clin Oncol. 28:21–28. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Schlumberger M, Tahara M and Wirth LJ:
Lenvatinib in radioiodine-refractory thyroid cancer. N Engl J Med.
372:18682015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Schlumberger M, Tahara M, Wirth LJ,
Robinson B, Brose MS, Elisei R, Habra MA, Newbold K, Shah MH, Hoff
AO, et al: Lenvatinib versus placebo in radioiodine-refractory
thyroid cancer. N Engl J Med. 372:621–630. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Brose MS, Nutting CM, Jarzab B, Elisei R,
Siena S, Bastholt L, de la Fouchardiere C, Pacini F, Paschke R,
Shong YK, et al: Sorafenib in radioactive iodine-refractory,
locally advanced or metastatic differentiated thyroid cancer: A
randomised, double-blind, phase 3 trial. Lancet. 384:319–328. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ito Y, Suzuki S, Ito K, Imai T, Okamoto T,
Kitano H, Sugitani I, Sugino K, Tsutsui H, Hara H, et al:
Tyrosine-kinase inhibitors to treat radioiodine-refracted,
metastatic, or recurred and progressive differentiated thyroid
carcinoma (Review). Endocr J. 63:597–602. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Perrier ND, Brierley JD and Tuttle RM:
Differentiated and anaplastic thyroid carcinoma: Major changes in
the American Joint Committee on Cancer eighth edition cancer
staging manual. CA Cancer J Clin. 68:55–63. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gül G, Sendur MA, Aksoy S, Sever AR and
Altundag K: A comprehensive review of denosumab for bone metastasis
in patients with solid tumors. Curr Med Res Opin. 32:133–145. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Miyauchi A, Kudo T, Miya A, Kobayashi K,
Ito Y, Takamura Y, Higashiyama T, Fukushima M, Kihara M, Inoue H,
et al: Prognostic impact of serum thyroglobulin doubling-time under
thyrotropin suppression in patients with papillary thyroid
carcinoma who underwent total thyroidectomy. Thyroid. 21:707–716.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Werner RA, Lückerath K, Schmid JS, Higuchi
T, Kreissl MC, Grelle I, Reiners C, Buck AK and Lapa C:
Thyroglobulin fluctuations in patients with iodine-refractory
differentiated thyroid carcinoma on lenvatinib treatment-initial
experience. Sci Rep. 6:280812016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kanda Y: Investigation of the freely
available easy-to-use software ‘EZR’ for medical statistics. Bone
Marrow Transplant. 48:452–458. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Levine ZH, Borchardt BR, Brandenburg NJ,
Clark CW, Muralikrishnan B, Shakarji CM, Chen JJ and Siegel EL:
RECIST versus volume measurement in medical CT using ellipsoids of
known size. Opt Express. 18:8151–8159. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Giordano L, Pilolli F, Toma S and Bussi M:
Parapharyngeal metastases from thyroid cancer: Surgical management
of two cases with minimally-invasive video-assisted technique. Acta
Otorhinolaryngol Ital. 35:289–292. 2015.PubMed/NCBI
|
|
21
|
Lamartina L, Borget I, Mirghani H, Al
Ghuzlan A, Berdelou A, Bidault F, Deandreis D, Baudin E, Travagli
JP, Schlumberger M, et al: Surgery for neck recurrence of
differentiated thyroid cancer: Outcomes and risk factors. J Clin
Endocrinol Metab. 102:1020–1031. 2017.PubMed/NCBI
|
|
22
|
Hui EP, Ma BB, King AD, Mo F, Chan SL, Kam
MK, Loong HH, Ahuja AT, Zee BC and Chan AT: Hemorrhagic
complications in a phase II study of sunitinib in patients of
nasopharyngeal carcinoma who has previously received high-dose
radiation. Ann Oncol. 22:1280–1287. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Epstein SS and Shaw HJ: Metastatic cancer
of the larynx as a cause of carotid-sinus syndrome. Cancer.
10:933–937. 1957. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ramadan S, Ugas MA, Berwick RJ, Notay M,
Cho H, Jerjes W and Giannoudis PV: Spinal metastasis in thyroid
cancer. Head Neck Oncol. 4:392012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Morbelli S, Ferrarazzo G, Pomposelli E,
Pupo F, Pesce G, Calamia I, Fiz F, Clapasson A, Bauckneht M, Minuto
M, et al: Relationship between circulating anti-thyroglobulin
antibodies (TgAb) and tumor metabolism in patients with
differentiated thyroid cancer (DTC): Prognostic implications. J
Endocrinol Invest. 40:417–424. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Neshandar Asli I, Siahkali AS, Shafie B,
Javadi H and Assadi M: Prognostic value of basal serum
thyroglobulin levels, but not basal antithyroglobulin antibody
(TgAb) levels, in patients with differentiated thyroid cancer. Mol
Imaging Radionucl Ther. 23:54–59. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Resteghini C, Cavalieri S, Galbiati D,
Granata R, Alfieri S, Bergamini C, Bossi P, Licitra L and Locati
LD: Management of tyrosine kinase inhibitors (TKI) side effects in
differentiated and medullary thyroid cancer patients. Best Pract
Res Clin Endocrinol Metab. 31:349–361. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yeung KT and Cohen EE: Lenvatinib in
advanced, radioactive iodine-refractory, differentiated thyroid
carcinoma. Clin Cancer Res. 21:5420–5426. 2015. View Article : Google Scholar : PubMed/NCBI
|
